Pharmaceutical industry welcomes the launch of Gavi’s new investment round and AVMA
On 20 June in Paris, Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners, co-hosted The Global Forum for Vaccine Sovereignty and Innovation.
The Forum launched Gavi’s 2026–2030 Investment Opportunity (IO) to support its next replenishment – which will raise funds for immunization in lower-income countries for Gavi’s sixth strategic period, from 2026 through 2030 (Gavi 6.0).
The Forum also saw the launch of the African Vaccine Manufacturing Accelerator (AVMA), an innovative financial mechanism, designed by Gavi in close collaboration with Africa Centres for Disease Control and Prevention (Africa CDC), to help vaccine manufacturers in Africa to scale up production and foster regional diversification of vaccine manufacturing.
Commenting on the launch of Gavi, the Vaccine Alliance’s 2026-2030 Investment Opportunity to support its next replenishment, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Dr. David Reddy, said:
“The pharmaceutical industry warmly welcomes the launch of Gavi’s new investment round.
“For over two decades, IFPMA members have collaborated with Gavi to combat infectious diseases and tackle some of the biggest global health challenges.
“As founding partners of Gavi, we are proud of the contribution our member companies make, and we remain dedicated to accelerating the development, production, and equitable distribution of safe, effective, and affordable vaccines.”
Commenting on the launch of the African Vaccine Manufacturing Accelerator (AVMA), Mr. Greg Perry, Assistant Director General, IFPMA said:
“The launch of the AVMA represents a groundbreaking financing instrument, to help both catalyze vaccine production within Africa and bolster global health resilience and equitable access to vaccines.
“For AVMA to have the maximum possible impact, it’s paramount that we create the environment for the life sciences to thrive, including robust regulatory and legal frameworks, forecasting mechanisms, demand generation, and efficient procurement strategies.
“The pharmaceutical industry is committed to playing our part in the collective efforts to forge a sustainable vaccine ecosystem and delivering equitable access to innovative vaccines across the continent.”
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
The value of prevention for economic growth and the sustainability of healthcare, social care and welfare systems (The European House – Ambrosetti)
Over the last decade, the EU economy has experienced slow growth, and it is not expected to grow substantially in the coming years. Additionally, the ongoing demographic and epidemiological transition is increasing pressure on public finances, particularly healthcare and social expenditure. The current permacrisis – encompassing geopolitical and climate-related challenges – exacerbates these issues and...
Read more
Only an urgent shift towards prevention-based healthcare can secure economic stability for EU health systems, experts say
As Governments of EU Member States present their medium-term fiscal structural plans on 20 September, a new report developed by The European House – Ambrosetti, supported by IFPMA and Vaccines Europe, notes that embedding preventative healthcare – in particular immunisation – into EU Member States’ fiscal policies is paramount to ensure the economic sustainability of...
Read moreAMATA statement on the Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035
On 29 August at the 74th WHO Africa Regional Committee Meeting in Brazzaville, Republic of Congo, the African Medicines Agency Treaty Alliance delivered a statement on Agenda item 10: Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035.
Read more